Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 1
2019 1
2020 2
2021 4
2022 3
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer.
Adam-Artigues A, Arenas EJ, Martínez-Sabadell A, Brasó-Maristany F, Cervera R, Tormo E, Hernando C, Martínez MT, Carbonell-Asins J, Simón S, Poveda J, Moragón S, Zazo S, Martínez D, Rovira A, Burgués O, Rojo F, Albanell J, Bermejo B, Lluch A, Prat A, Arribas J, Eroles P, Cejalvo JM. Adam-Artigues A, et al. Sci Adv. 2022 May 20;8(20):eabk2746. doi: 10.1126/sciadv.abk2746. Epub 2022 May 20. Sci Adv. 2022. PMID: 35594351 Free PMC article.
A PERK-Specific Inhibitor Blocks Metastatic Progression by Limiting Integrated Stress Response-Dependent Survival of Quiescent Cancer Cells.
Calvo V, Zheng W, Adam-Artigues A, Staschke KA, Huang X, Cheung JF, Nobre AR, Fujisawa S, Liu D, Fumagalli M, Surguladze D, Stokes ME, Nowacek A, Mulvihill M, Farias EF, Aguirre-Ghiso JA. Calvo V, et al. Among authors: adam artigues a. Clin Cancer Res. 2023 Dec 15;29(24):5155-5172. doi: 10.1158/1078-0432.CCR-23-1427. Clin Cancer Res. 2023. PMID: 37982738
AXL - a new player in resistance to HER2 blockade.
Adam-Artigues A, Arenas EJ, Arribas J, Prat A, Cejalvo JM. Adam-Artigues A, et al. Cancer Treat Rev. 2023 Dec;121:102639. doi: 10.1016/j.ctrv.2023.102639. Epub 2023 Oct 7. Cancer Treat Rev. 2023. PMID: 37864955 Free article. Review.
miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+ Breast Cancer.
Cabello P, Torres-Ruiz S, Adam-Artigues A, Forés-Martos J, Martínez MT, Hernando C, Zazo S, Madoz-Gúrpide J, Rovira A, Burgués O, Rojo F, Albanell J, Lluch A, Bermejo B, Cejalvo JM, Eroles P. Cabello P, et al. Among authors: adam artigues a. Cancers (Basel). 2023 Apr 4;15(7):2138. doi: 10.3390/cancers15072138. Cancers (Basel). 2023. PMID: 37046799 Free PMC article.
MicroRNAs as a clue to overcome breast cancer treatment resistance.
Garrido-Cano I, Pattanayak B, Adam-Artigues A, Lameirinhas A, Torres-Ruiz S, Tormo E, Cervera R, Eroles P. Garrido-Cano I, et al. Among authors: adam artigues a. Cancer Metastasis Rev. 2022 Mar;41(1):77-105. doi: 10.1007/s10555-021-09992-0. Epub 2021 Sep 15. Cancer Metastasis Rev. 2022. PMID: 34524579 Free PMC article. Review.
Identification of a Two-MicroRNA Signature in Plasma as a Novel Biomarker for Very Early Diagnosis of Breast Cancer.
Adam-Artigues A, Garrido-Cano I, Carbonell-Asins JA, Lameirinhas A, Simón S, Ortega-Morillo B, Martínez MT, Hernando C, Constâncio V, Burgues O, Bermejo B, Henrique R, Lluch A, Jerónimo C, Eroles P, Cejalvo JM. Adam-Artigues A, et al. Cancers (Basel). 2021 Jun 7;13(11):2848. doi: 10.3390/cancers13112848. Cancers (Basel). 2021. PMID: 34200463 Free PMC article.
Delivery of miR-200c-3p Using Tumor-Targeted Mesoporous Silica Nanoparticles for Breast Cancer Therapy.
Garrido-Cano I, Adam-Artigues A, Lameirinhas A, Blandez JF, Candela-Noguera V, Lluch A, Bermejo B, Sancenón F, Cejalvo JM, Martínez-Máñez R, Eroles P. Garrido-Cano I, et al. Among authors: adam artigues a. ACS Appl Mater Interfaces. 2023 Aug 16;15(32):38323-38334. doi: 10.1021/acsami.3c07541. Epub 2023 Aug 7. ACS Appl Mater Interfaces. 2023. PMID: 37549382 Free PMC article.
16 results